Participant Survey Results in a Diverse Community‐Based Alzheimer’s Disease Blood Test Study

An AD blood test can be a feasible and widely used screening tool in a diverse population. To continue improving AD research, it is imperative to consider historically underrepresented populations and the barriers that may affect their initial and continuing participation. Broadening recruitment efforts to include varied sources across many populations, proactively addressing transportation needs, tailoring experiences to be inclusive of education levels and physical abilities, and careful consideration of compensation are some aspects of clinical studies that can create a positive impact on inclusivity and provide real-world application to AD biomarker testing.